As AstraZeneca completes the acquisition of Almirall’s respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca.
The deal includes the inhalation R&D company Almirall Sofotec as well as a number of inhalers, including the Eklira/Bretaris/Tudorza aclidinium DPI, the Duaklir Genuair aclidinium/formoterol DPI, and several other inhaled drugs in the pipeline.
AstraZeneca CEO Pascal Soriot said, “I am delighted to welcome our Almirall colleagues to AstraZeneca. Respiratory disease is one of our company’s key therapeutic areas, and the combination of these exciting portfolios reinforces our long-term commitment to patients with asthma and COPD. Our expanded product and device offering will enable us to bring better treatment options to patients.”
Read the AstraZeneca press release.
Read the Almirall notice.
